RT Journal Article
SR Electronic
T1 Long COVID In Adults at 12 Months After Mild-to-Moderate SARS-CoV-2 Infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.12.21255343
DO 10.1101/2021.04.12.21255343
A1 Boscolo-Rizzo, Paolo
A1 Guida, Francesco
A1 Polesel, Jerry
A1 Marcuzzo, Alberto Vito
A1 Capriotti, Vincenzo
A1 D’Alessandro, Andrea
A1 Zanelli, Enrico
A1 Marzolino, Riccardo
A1 Lazzarin, Chiara
A1 Antonucci, Paolo
A1 Sacchet, Erica
A1 Tofanelli, Margherita
A1 Borsetto, Daniele
A1 Gardenal, Nicoletta
A1 Pengo, Martino
A1 Tirelli, Giancarlo
YR 2021
UL http://medrxiv.org/content/early/2021/04/13/2021.04.12.21255343.abstract
AB Background In a proportion of patients recovered from the acute COVID-19 phase, a variable range of symptoms has been observed to persist for at least 6-months.Objectives The main aim of this study was to evaluate the prevalence of COVID-related symptoms 12-months after the onset of mild-to-moderate disease.Methods Prospective study based on structured questionnaires and additional outcomes.Results 304/354 patients completing the survey at baseline also completed the follow-up interview (85.9%; median [range] age, 47 [18-76] years; 185 [60.9%] women). Persistence of at least one symptom at 12-months follow-up was reported by 161 patients (53.0%). The most commonly reported symptom of long COVID was felt tired (n=83, 27.3%), followed by smell or taste impairment (n=67, 22.0%), shortness of breath (n=39, 12.8%) and muscle pain (n=28, 9.2%). Being females (OR=1.64; 95% CI: 1.00-2.70), aged between 40-54 (OR=1.92; 95% CI: 1.07-3.44), having a BMI ≥25 (OR=1.67; 95% CI: 1.00-2.78), and experiencing more symptoms during the acute phase of the disease (OR=8.71 for ≥8 symptoms; 95% CI: 2.73-27.76) were associated with long COVID. Persistence of symptoms showed a significant impact on quality of life (p<0.0001) and depression scale scores (p=0.0102).Conclusion More than half of patients with previous mild-to-moderate symptomatic COVID-19 complained the persistence of at least one symptom 12-months after the onset of the illness.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee of the Friuli Venezia Giulia Region (CEUR-2020-Os- 156)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article